Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine? Approximating the funding to the University of Oxford for the research and development of the ChAdOx vaccine technology

Samuel Cross, Yeanuk Rho, Henna Reddy, Toby Pepperrell, View ORCID ProfileFlorence Rodgers, Rhiannon Osborne, Ayolola Eni-Olotu, Rishi Banerjee, View ORCID ProfileSabrina Wimmer, View ORCID ProfileSarai Keestra
doi: https://doi.org/10.1101/2021.04.08.21255103
Samuel Cross
1School of Medicine, Imperial College London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yeanuk Rho
1School of Medicine, Imperial College London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henna Reddy
2Medical Sciences Division, University of Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toby Pepperrell
1School of Medicine, Imperial College London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florence Rodgers
1School of Medicine, Imperial College London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Florence Rodgers
Rhiannon Osborne
3School of Clinical Medicine, University of Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ayolola Eni-Olotu
1School of Medicine, Imperial College London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rishi Banerjee
1School of Medicine, Imperial College London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabrina Wimmer
4University Medical Center Groningen, Groningen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sabrina Wimmer
Sarai Keestra
5Amsterdam UMC, University of Amsterdam, the Netherlands
6Department of Global Health & Development, London School of Hygiene and Tropical Medicine, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sarai Keestra
  • For correspondence: s.m.keestra@amsterdamumc.nl
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives The Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19 or Vaxzevira) builds on nearly two decades of research and development (R&D) into Chimpanzee adenovirus-vectored vaccine (ChAdOx) technology at the University of Oxford. This study aims to approximate the funding for the R&D of the ChAdOx technology and the Oxford-AstraZeneca vaccine, and assess the transparency of funding reporting mechanisms.

Design We conducted a scoping review and publication history analysis of the principal investigators to reconstruct the funding for the R&D of the ChAdOx technology. We matched award numbers with publicly-accessible grant databases. We filed Freedom Of Information (FOI) requests to the University of Oxford for the disclosure of all grants for ChAdOx R&D.

Results We identified 100 peer-reviewed articles relevant to ChAdOx technology published between 01/2002 and 10/2020, extracting 577 mentions of funding bodies from funding acknowledgement statements. Government funders from overseas were mentioned 158 (27.4%), the U.K. government 147 (25.5%) and charitable funders 138 (23.9%) times. Grant award numbers were identified for 215 (37.3%) mentions, amounts were available in the public realm for 121 (21.0%) mentions. Based on the FOIs, until 01/2020, the European Commision (34.0%), Wellcome Trust (20.4%) and CEPI (17.5%) were the biggest funders of ChAdOx R&D. From 01/2020, the U.K. Department of Health and Social Care was the single largest funder (89.3%). The identified R&D funding was £104,226,076 reported in the FOIs, and £228,466,771 reconstructed from the literature search.

Conclusions Our study identified that public funding accounted for 97.1-99.0% of the funding towards the R&D of ChAdOx and the Oxford-AstraZeneca vaccine. We furthermore encountered a severe lack of transparency in research funding reporting mechanisms.

Strengths and limitations of this study

  • This is the first study that analysed the R&D funding and funders contributing to the Oxford-AstraZeneca vaccine and the underlying ChAdOx technology.

  • We used multiple sources and methods to approximate the R&D funding of the Oxford-AstraZeneca Vaccine and ChAdOx technology.

  • We cross-matched award numbers with all publicly-accessible databases by major funders of R&D.

  • Freedom Of Information requests were a useful method to identify R&D funding, but face limitations in their scope of data collection.

  • Integration of the two data sets was not possible due to insufficient grant information and lack of award numbers in funding acknowledgement statements in peer-reviewed articles.

Competing Interest Statement

Competing interest statement: The authors of this paper are all members of Universities Allied for Essential Medicines Europe. S.W. is a member of the Executive Committee of Universities Allied for Essential Medicine Global and F.R. is the National Coordinator of Universities Allied for Essential Medicines U.K. S.K. and R.O. are members of the PHM and the WHO Watch initiative. R.O. is currently Policy Director for Students for Global Health U.K. However, views expressed in this paper are their own and are not necessarily shared with the organisations the authors are affiliated with.

Funding Statement

Funding statement: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Not relevant

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Supplementary Information is available for this paper. Any correspondence and requests for materials should be addressed to Ms. Sarai Keestra, Amsterdam UMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands, or by email at s.m.keestra@amsterdamumc.nl.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted April 10, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine? Approximating the funding to the University of Oxford for the research and development of the ChAdOx vaccine technology
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine? Approximating the funding to the University of Oxford for the research and development of the ChAdOx vaccine technology
Samuel Cross, Yeanuk Rho, Henna Reddy, Toby Pepperrell, Florence Rodgers, Rhiannon Osborne, Ayolola Eni-Olotu, Rishi Banerjee, Sabrina Wimmer, Sarai Keestra
medRxiv 2021.04.08.21255103; doi: https://doi.org/10.1101/2021.04.08.21255103
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine? Approximating the funding to the University of Oxford for the research and development of the ChAdOx vaccine technology
Samuel Cross, Yeanuk Rho, Henna Reddy, Toby Pepperrell, Florence Rodgers, Rhiannon Osborne, Ayolola Eni-Olotu, Rishi Banerjee, Sabrina Wimmer, Sarai Keestra
medRxiv 2021.04.08.21255103; doi: https://doi.org/10.1101/2021.04.08.21255103

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Policy
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (413)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (158)
  • Dermatology (97)
  • Emergency Medicine (248)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (393)
  • Epidemiology (8547)
  • Forensic Medicine (4)
  • Gastroenterology (383)
  • Genetic and Genomic Medicine (1742)
  • Geriatric Medicine (167)
  • Health Economics (371)
  • Health Informatics (1237)
  • Health Policy (619)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (372)
  • Infectious Diseases (except HIV/AIDS) (10279)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1669)
  • Nursing (97)
  • Nutrition (248)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (926)
  • Ophthalmology (263)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (112)
  • Palliative Medicine (40)
  • Pathology (252)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (246)
  • Primary Care Research (207)
  • Psychiatry and Clinical Psychology (1762)
  • Public and Global Health (3832)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (319)
  • Respiratory Medicine (519)
  • Rheumatology (207)
  • Sexual and Reproductive Health (165)
  • Sports Medicine (157)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (74)